GSK: presents HIV data AT IDWeek 2021
(CercleFinance.com) - ViiV Healthcare is presenting data for Dovato (dolutegravir/lamivudine).
ViiV Healthcare, the global HIV company majority-owned by GlaxoSmithKline with Pfizer and Shionogi, today presented three-year results from the TANGO study at IDWeek 2021, which is being held virtually from 29 September to 3 October.
The Phase III TANGO study is the third trial to provide long-term evidence for Dovato, reinforcing its use as a viable change option for people living with HIV.
The results showed that the Dovato (dolutegravir/lamivudine) two-drug regimen (2DR) continued to demonstrate efficacy.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
ViiV Healthcare, the global HIV company majority-owned by GlaxoSmithKline with Pfizer and Shionogi, today presented three-year results from the TANGO study at IDWeek 2021, which is being held virtually from 29 September to 3 October.
The Phase III TANGO study is the third trial to provide long-term evidence for Dovato, reinforcing its use as a viable change option for people living with HIV.
The results showed that the Dovato (dolutegravir/lamivudine) two-drug regimen (2DR) continued to demonstrate efficacy.
Copyright (c) 2021 CercleFinance.com. All rights reserved.